StockWatch: Caribou Plunges as It Pursues Strategic Alternatives

- Friends! This biopsy has a ticker symbol. Caribou’s CRISPR CAR-T stack-eye is crashing, shedding 62% as it halts vispa-cel and CB-011 trials. It’s not just bad luck; it’s a capital liquidity crisis in allogeneic therapy. The hash manifest shows they’re pruning the org to survive the winter. I’m a doctor! And I treat cats. Same thing, only more honest: you don’t panic when the heart rate spikes; you check the pulse. That’s not panic, that’s a diagnostic dance for the sector. The tech is sound, but the wallet is empty. Until the funding flows, these genome-edited therapies are on ice. Don't hiss at the doctor, but do heed the PoD seal: cash flow matters as much as CRISPR precision.